tbuckley/cabot-search huggingface dataset:
Interleukin-2 (IL-2) with high-dose chemotherapy (HDC) and autologous hematopoietic stem-cell transplantation (AHST) for poor-risk metastatic breast cancer (MBC)
Authors: Y. C. C. Cheng, G. Rondón, D. R. Couriel, M. J. De Lima, C. Hosing, I. F. Khouri, S. A. Giralt, J. L. Gajewski, R. E. Champlin, N. T. Ueno
Journal: Journal of Clinical Oncology (2004)

6664 Background: We found that patients with MBC who had a > 50% reduction in Swenerton score after induction standard-dose chemotherapy (SDC) had higher rates of complete response (CR) conversion and survival after HDC/AHST than those with ≤ 50% reduction (Biol Blood Marrow Transplant. 9:330, 2003), with disease progression the major cause of failure. We studied the effect of ex vivo IL-2 activation of peripheral blood progenitor cells (PBPCs) and IL-2 maintenance therapy after AHST for poor-risk MBC. Methods: Patients with MBC with < CR to SDC were assigned to 4 days' G-CSF for PBPC mobilization (Grp 1) or 8 days' IL-2 (1.8 mIU/day s.c.) plus 4 days' G-CSF (Grp 2). HDC was cyclophosphamide (2.0 g/m2), carmustine (150 mg/m2), and thiotepa (240 mg/m2) i.v. daily from day –7 to –5. PBPCs were treated ex vivo with IL-2 (6000 IU/ml) for 24 hours and reinfused on day 0. Patients were given low-dose IL-2 (0.3 mIU/m2/day s.c.) from day 1 x 21 days, followed by 4 days' rest, then intermediate-dose IL-2 (1 mIU/m2/day s.c.) for 10 days, then 14 days' rest, and then 10 more days of intermediate-dose IL-2. The IL-2 dose was held if ≥ grade 3 toxicity occurred. Results: Median age of the 24 patients (10 in Grp 1, 14 in Grp 2) was 45.5 y (range 33–56). Median Swenerton score before HDC/AHST was 5 (range 0–16); 3 patients had > 50% reduction in that score after SDC. PBPCs were mobilized and activated in all patients. Median number of low-dose IL-2 doses given was 14 in Grp 1 (range 2–21) and 19.5 in Grp 2 (range 0–21); intermediate-dose IL-2 was held in 3 patients in Grp 1 and 3 in Grp 2. Major adverse effects from IL-2 were fever and rash; no treatment-related mortality was seen. At 689 days' median follow-up (range 94–1525), median progression-free survival was reached at 306 days. 7 patients are alive and free of disease progression at a median of 565 days (range, 94–985). Estimated 2-year progression-free and overall survival rates were 28% and 57%. Conclusions: IL-2 for PBPC mobilization, ex vivo activation, and maintenance therapy after HDC/AHST was feasible. Some patients with poor-risk MBC survived progression-free for more than 1 year. No significant financial relationships to disclose.
F<scp>ifty</scp> Y<scp>ears</scp> <scp>of</scp> R<scp>esearch</scp> <scp>in</scp> ARDS.Cell-based Therapy for Acute Respiratory Distress Syndrome. Biology and Potential Therapeutic Value
Authors: John G. Laffey, Michael A. Matthay
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Section:ChooseTop of pageAbstract <<Lack of Therapies for ARD...Stem CellsMSCsMechanisms of Action of M...How MSCs Produce Their Ef...Recent Translational and ...Advancing the Therapeutic...ConclusionsReferencesCITING ARTICLES
EXERCISE TEST PREDICTS BOTH CARDIOVASCULAR AND NON-CARDIOVASCULAR MORTALITY IN PATIENTS WITHOUT CARDIOVASCULAR DISEASE
Authors: Nora Sydo, Tibor Sydó, Bela Merkely, Shausha Farooq, Nasir Hussain, Karina Gonzalez Carta, Francisco Lopez-Jimenez, Adelaide Arruda-Olson, Thomas Allison
Journal: Journal of the American College of Cardiology (2017)
Correlation of gastrointestinal stromal tumor (GIST) gene expression signatures and response to imatinib mesylate in the Radiation Therapy Oncology Group phase II clinical trial S-0132
Authors: L. Rink, Y. Skorobogatko, A. Kossenkov, M. G. Belinsky, T. F. Pajak, M. von Mehren, M. F. Ochs, B. Eisenberg, A. K. Godwin
Journal: Journal of Clinical Oncology (2009)

10533 Background: Despite the known efficacy of imatinib mesylate (IM) in metastatic GIST, both primary and secondary drug resistance remain a clinical problem. Therefore, future management of GIST may benefit from further molecular characterization associated with IM treatment. Methods: A recently completed prospective phase II trial of neoadjuvant/adjuvant IM treatment for advanced primary and recurrent operable GISTs included gene expression profiling using oligonucleotide microarrays on tumor samples obtained before and after neoadjuvant IM therapy for 8 to 12 weeks. Fifty-two analyzable patients were classified according to changes in tumor size after IM based on CT scan measurements. A response was defined as &gt;25% tumor reduction. Gene profiling data were then evaluated with SAM analysis (FDR = 10%) to identify differentially expressed genes (in pre-treatment GIST samples). In addition, a custom siRNA library was designed targeting these genes and a mid-throughput siRNA synthetic lethal screening approach was used to evaluate the ability of each to sensitize GIST cells to IM. Results: Thirty-eight genes were expressed at significantly lower levels in the pre-treatment samples of tumors that rapidly responded to IM. Eighteen of these genes encoded KRAB domain containing zinc finger (KRAB-ZNF) transcriptional repressors. Importantly, ten KRAB-ZNF genes mapped to a single locus on chromosome 19p, and a subset of these predicted likely response to IM-based therapy in a naïve panel of GISTs. Further evaluation revealed that modifying in vitroexpression of genes via RNAi approaches within this predictive response signature enhanced the sensitivity of GIST cells to IM. Conclusions: Using clinical samples from a prospective neoadjuvant/adjuvant phase II trial we have identified a genetic signature which includes KRAB-ZNF 91 subfamily members that may be both predictive of and functionally associated with likely rapid response to short-term IM treatment and which may provide a prognostic biomarker identifying patients who will benefit from it. [Table: see text]
Analysis of the state of lymphocyte infiltration in patients with NSCLC.
Authors: Eduardo Richardet, Martin Eduardo Richardet, Patricia Andrea Hernandez, Aldo Alejandro Riso, Matias Nicolas Cortes, Matias Molina, Eugenia Pacher, Pablo Companys, Luciana Paola Acosta, Luciano Salvador Dicalbo
Journal: Journal of Clinical Oncology (2015)

e19125 Background: Current evidence makes reference to the potential role of tumor-infiltrating lymphocytes (TILs) as a prognostic factor in many types of tumors; in non-small cell lung cancer (NSCLC) the relationship is not well determined. TILs are being studied with different methods such as immunohistochemistry and optical microscopy. The primary endpoint is to identify TILS in patients with NSCLC, classified as present or absent, and its relation to progression-free survival (PFS) and overall survival (OS). Our secondary endpoint is to establish the relationship between the TILS and treatment received. Methods: Retrospective and analytical case study of Instituto Oncológico de Córdoba, from 2004 to 2014. 166 patients with stage IIIB and IV NSCLC were analyzed. TILS are descriptively classified as present or absent. Survival curves were calculated using the Kaplan-Meier method. Results: 59% of patients had adenocarcinoma and 41% squamous cell carcinoma. 70% were men. 82% were smokers. 58% with squamous histology had TILS. 65% with adenocarcinoma, showed TILS. Regarding the first-line treatment, 55% of patients with TILS present, received carboplatin-paclitaxel (CP), 45% gemcitabine-cisplatin (GC). In patients with adenocarcinoma, 62% with infiltrate present and 63% with absent, received CP. 38% with infiltrate present and 37% with absent, treated with GC. As for patients with squamous histology, 64% with infiltrate received CP and 36% GC. 63% of patients with absent treated with CP and 37% with GC. Regarding patients with adenocarcinoma, those with TILS present had higher PFS and OS; 8.86 and 13.43 months respectively, compared to patients with absent, 3.78 and 7.9 months. These differences were statistically significant (PFS: p = 0.000002 and OS: p = 0.003). The patients with squamous cell carcinoma with TILS had 6.78 and 12 months PFS and OS respectively. Those who had infiltrated absent had a PFS of 3.96 months and OS of 6.37 months. These differences were also statistically significant (PFS: p = 0.003 OS p = 0.001). Conclusions: Our study shows that patients whose pathological samples showed inflammatory infiltrate had higher OS and PFS. The presence of TILS could be used as an important prognostic factor in this patient population
Correlation of SMAD4 mutational status and local or metastatic progression in patients with pancreatic cancer.
Authors: Olfa Derbel, Arnaud de la Fouchardière, Julien Peron, Michel Rivoire, Françoise Desseigne, Pierre Meeus, Patrice Peyrat, Pierre Heudel, Mattia Stella, Severine Racadot, Christelle DE LA Fouchardiere
Journal: Journal of Clinical Oncology (2012)

e14730 Background: Pancreatic cancer remains resistant to many key cytotoxic chemotherapeutic agents and novel targeted therapies. The molecular heterogeneity of this cancer may account for therapy failures to date, although the growing arsenal of novel targeted agents could translate into patient survival. A better understanding of the cellular and molecular features of advanced disease will afford new opportunities for investigation, therapeutic intervention and clinical management of patients afflicted with pancreatic cancer. Methods: This study examined the expression profiles of Smad4 in 45 samples of surgically resected pancreatic cancer. Of these 45 patients, 32 underwent pancreaticoduodenectomy. The clinicopathological parameters, the histologic features were determined and correlated to the stage at initial diagnosis, patterns of failure (locally advanced v metastatic disease) and the status SMAD4 genes. Results: Among the 45 patients, 40% of patients died with metastatic disease and 15 % died with locally advanced evolution. SMAD4 genetic status was determined in 25 patients and seems to be correlated with a high grade histologic features and progression to metastasis. Complementary data about correlation between the mutational status of SMAD4 and survival will be presented during congress. Conclusions: SMAD4 gene inactivation seems to be associated with poorer prognosis and disease progression. Prospective validation of SMAD4 as a predictive biomarker may personalize treatment strategies for patients with pancreatic cancer.
TAVR IS SAFE AND IMPROVES CARDIAC FUNCTION IN PATIENTS WITH EXTREMELY LOW EJECTION FRACTIONS
Authors: Chase R. Brown, Robert Li, Saif Anwaruddin, Nimesh Desai, Prashanth Vallabhajosyula, Jay Giri, Howard Herrmann, Joseph Bavaria, Wilson Szeto, Matthew Williams
Journal: Journal of the American College of Cardiology (2017)
TIME RELATED BENEFIT OF ANTIPLATELET THERAPY ON CORONARY REPERFUSION IN ST-ELEVATION MYOCARDIAL INFARCTION (STEMI) PATIENTS
Authors: Martino Pepe, Filippo Masi, Nicola Signore, Alessandro Santo Bortone, Annagrazia Cecere, Antonio Tito, Domenico Zanna, Donato Quagliara, Stefano Favale
Journal: Journal of the American College of Cardiology (2017)
Patient-reported symptoms and Canadian Health Utility scores in esophageal cancer patients.
Authors: Mark Doherty, Yvonne Leung, Hiten Naik, Devalben Patel, Lawson Eng, Qin Quinn Kong, Catherine Brown, Osvaldo Espin-Garcia, Ashlee Vennettilli, Daniel John Renouf, Olusola Olusesan Faluyi, Jennifer J. Knox, Helen Mackay, Rebecca Wong, David Cella, Gail Elizabeth Darling, Doris Howell, Nicole Mittmann, Wei Xu, Geoffrey Liu
Journal: Journal of Clinical Oncology (2015)

6607 Background: Health utility scores (HUS) are an increasingly important tool to help determine the cost-effectiveness of therapies worldwide. The EQ-5D-3L is a validated tool for deriving HUS, with reference data in numerous populations, but there is limited information on the role that individual symptom complexes (SC) play in determining HUS in Esophageal cancer (EC) patients. Methods: A cross-sectional survey of EC patients at Princess Margaret Cancer Centre (2012-2014) assessed EQ-5D-3L and FACT-E. EQ-5D scores were converted to HUS using Canadian references. SC were developed: domains from FACT-E were identified and grouped to represent symptoms such as pain, dysphagia, fatigue, dyspnea, nausea and loss of appetite. Multivariable regression analysis was performed to assess associations between SC and HUS, adjusting for age, sex, and stage of disease. Results: Of 197 patients, median age was 67 (range 32-93) years, 76% were male, with stage I/II-IVA/IVB (6%/66%/28%) disease. Mean (SE) HUS were 0.90(0.05), 0.82(0.01), and 0.73(0.03) for stage I/II-IVA/IVB disease. Correlations between HUS and symptom scores are summarised in the table below. SC constructed for appetite, pain, nausea and fatigue showed significant association with HUS. Conclusions: A number of prevalent and important symptoms and SC correlated well with EQ5D-derived HUS, particularly appetite, pain, nausea, and fatigue. The strongest association was seen with pain. These relationships provide additional support for using these HUS in health-economic models. Mutivariable regression model results. Parameter β Standard Error p Appetite -0.012 0.004 0.0013 Dysphagia 0.005 0.003 0.11 Pain -0.023 0.005 <.0001 Nausea -0.022 0.007 0.0036 Fatigue 0.088 0.026 0.0008 Dyspnea 0.034 0.042 0.43 Age -0.002 0.001 0.0219 Sex (F vs M) -0.006 0.022 0.81 Stage (early vs late) 0.072 0.022 0.0011
NON ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION SECONDARY TO PARADOXICAL EMBOLISM VIA A PATENT FORAMEN OVALE
Authors: Adriana Rauseo, Uday G. Sandhu, Raymundo A. Quintana-Quezada, Ala Eddin S. Sagar, Sam Chitsaz, Surya S. Palakuru, Kamran Boka
Journal: Journal of the American College of Cardiology (2017)
Phase II study of 250 mg gefitinib in advanced squamous cell carcinoma of the head and neck (SCCHN)
Authors: M. A. Kane, E. Cohen, M. List, B. Mehrotra, D. Gustin, A. Mauer, D. Cella, E. Vokes
Journal: Journal of Clinical Oncology (2004)

5586 Background: Inhibition of EGFR has demonstrated benefit in SCCHN. Treatment of patients with incurable SCCHN with 500 mg gefitinib PO QD produced an 11% response rate, 53% disease control rate and 29% overall survival at 1 year (JCO 21: 1980, 2003). However better tolerability and equal efficacy to this dose was reported in non-small cell lung cancer patients treated with 250 mg gefitinib . This phase II study of 250 mg gefitinib evaluated activity, toxicity and VEGF levels in patients with advanced SCCHN. Methods: Patients had incurable SCCHN, measurable disease, no prior EGFR-based therapy, ECOG PS ≤ 2, intact organ function, and ability to give informed consent. Patients received gefitinib 250 mg QD PO or via feeding tube. The primary endpoint was objective response rate (CR + PR). Correlative studies included plasma VEGF levels and quality of life measurements using FACT HN Symptom Index score. Results: 65 patients were enrolled from 6/02 to 11/03: 43 men, 22 women; median age 57.5 years; 19 local recurrence only, 22 metastatic only, 24 both. 56 had PS 0 or 1, and 9 had PS 2. All patients had prior radiotherapy; 28 (43%) had prior chemotherapy for recurrent/metastatic disease. 32 (49%) patients received gefitinib via feeding tube. Drug-related toxicity consisted of dermatologic (64%, no grade 3/4), diarrhea (30%, 2 patients with grade 3), and nausea (13%, 1 patient with grade 3). No grade 4 toxicities were observed. 56 patients are evaluable for best response: 2 (3.5%) PR, 19 (34%) SD, and 35 (63%) PD. Mean plasma VEGF levels (Nl < 55 pg/ml) were 162.6 pg/ml pre-therapy and 156.2 pg/ml after 8 weeks. Mean (± S.D.) pre-therapy VEGF level in patients with PR or SD as best response was 113 ± 92 pg/ml compared with 190 ± 357 pg/ml in PD patients (P = 0.26, NSD). Mean quality of life scores were stable: baseline 25.6, 4 weeks 25.9 and 8 weeks 26.36. Conclusions: Gefitinib 250mg QD is well tolerated in advanced SCCHN with modest benefit and without significant deterioration in overall quality of life scores. Plasma VEGF levels were lower in patients with PR or SD compared with PD (NSD) and did not change from baseline after 8 weeks of gefitinib 250 mg. Supported by Astra Zeneca. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Aventis
RNAI-BASED THERAPEUTIC TARGETING FACTOR 12 AS A PROPHYLACTIC TREATMENT FOR THROMBOEMBOLISM
Authors: Stacey Melquist, Lauren Almeida, Holly Hamilton, Tao Pei, Qili Chu, Julia Hegge, Tracie Milarch, Jessica Montez, Jason Klein, Aaron Andersen, Megan Walters, Christine Chapman, Edie Doss, Zhen Li, David Lewis, Steven Kanner
Journal: Journal of the American College of Cardiology (2017)
Pan-Canadian rash trial with EGFR inhibitors.
Authors: Barbara L. Melosky, Helen Anderson, Ronald L. Burkes, Quincy S. Chu, Desiree Hao, Vincent Ho, Cheryl Ho, Christopher W. Lee, Nevin Murray, Natasha B. Leighl, Sophie Sun, Robert Davis Winston, Janessa J. Laskin
Journal: Journal of Clinical Oncology (2014)

8013 Background: Erlotinib prolongs survival in advanced non-small cell lung cancer (NSCLC), as a first-line treatment for EGFR mutation, and second-/third-line upon progression on chemotherapy. Rash is a major side effect of erlotinib; studies have retrospectively illustrated a relationship between rash and efficacy. The primary objective of this study was to determine the optimal treatment of rash secondary to erlotinib Methods: The Pan Canadian Rash Trial studied rash in patients who received erlotinib for advanced NSCLC in the second or third-line setting. This trial was initiated before EGFR mutational testing was available. Patients were randomized to one of three arm: Prophylactic (Arm 1) minocycline (150 po bid) on day 1 of erlotinib; Reactive (Arm 2) treatment with topical clindamycin + hydrocortisone +/- minocycline upon rash occurrence depending on grade; Observation (Arm 3) no treatment of rash unless severe (Gr 3). Endpoints included the overall incidence and severity of rash and relationship to survival. Results: 150 patients were enrolled. 75% were Caucasian and 76% were current/former smokers. Overall incidence of rash was 83%. Time to occurrence of rash was significantly longer in Arm 1. (Table) Prophylactic minocycline reduced the probability of rash by 39.8% compared to Arms 2 and 3 combined (odds ratio 0.602, p = 0.3210). The incidence of Grade 3 rash was greater in Arm 3 (34.1%) versus Arms 1 (14.3%) and 2 (9.5%). Patients in Arm 1 were on erlotinib 50% longer than in arms 2 and 3 (6.34 months vs 4.02 and 4.16 respectively). Although not statistically significant, Arm 1 had the longest overall survival. Conclusions: Incidence of rash secondary to erlotinib treatment is common. Prophylactic minocycline reduced occurrence and severity of rash, was well tolerated and conferred a non-significant survival advantage. This may reflect improvement in patient compliance. Observation until severe rash (Gr 3) led to the worst outcome. Prophylactic treatment did not reduce erlotinib efficacy, and should be considered in patients upon initiation of erlotinib therapy. Clinical trial information: NCT00473083.Time to first presentation of rash, all grades. Incidence of rash n (%) Median (days) Mean (days) P value ARM 1 (N=50) 42 (84) 12.0 17.4 p 0.0147 ARM 2 (N=50) 42 (84) 9.0 13.3 Arm 3 (N=50) 41 (82) 8.0 12.0
THE UTILITY OF LEFT ATRIAL APPENDAGE HOUNSFIELD UNIT AND THE RATIO OF LEFT ATRIAL APPENDAGE/ASCENDING AORTA HOUNSFIELD UNIT FOR DETECTING LEFT ATRIAL APPENDAGE THROMBUS
Authors: Kazuhiro Osawa, Rine Nakanishi, Dong Li, Eranthi Jayawardena, Nicholas Kim, Sina Rahmani, Negin Nezarat, Hong Qi, Matthew Budoff
Journal: Journal of the American College of Cardiology (2017)
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial
Authors: E Magnus Ohman, Matthew T Roe, P Gabriel Steg, Stefan K James, Thomas J Povsic, Jennifer White, Frank Rockhold, Alexei Plotnikov, Hardi Mundl, John Strony, Xiang Sun, Steen Husted, Michal Tendera, Gilles Montalescot, M Cecilia Bahit, Diego Ardissino, Héctor Bueno, Marc J Claeys, Jose C Nicolau, Jan H Cornel, Shinya Goto, Róbert Gábor Kiss, Ümit Güray, Duk-Woo Park, Christoph Bode, Robert C Welsh, C Michael Gibson
Journal: The Lancet (2017)
Nelarabine Alone or in Combination in High Risk Childhood / Adolescent and Young Adults (AYA) T- Cell Acute Lymphoblastic Leukemia
Authors: Benoit Brethon, Laetitia Morel, Arnaud Petit, Etienne Lengliné, Aurelie Cuinet, Genevieve Vaudre, Thierry Leblanc, Marie-Dominique Tabone, Guy Leverger, Nicolas Boissel, André Baruchel
Journal: Blood (2014)
EFFICACY AND SAFETY OF TRANSULNAR COMPARED TO TRANSRADIAL ARTERIAL ACCESS IN PATIENTS UNDERGOING CORONARY ANGIOGRAPHY: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: Anene Ukaigwe, Giselle Baquero, Pragya Shrestha, Paras Karmacharya, Ian Gilchrist
Journal: Journal of the American College of Cardiology (2017)
ISOLATED SYSTOLIC HYPERTENSION AND PULSE PRESSURE ARE ASSOCIATED WITH HIGH-SENSITIVITY CARDIAC TROPONIN-T AND NT-PRO BNP IN OLDER ADULTS
Authors: Nidhi Madan, Alexandra Lee, Kunihiro Matsushita, Ron Hoogeveen, Christie Ballantyne, Elizabeth Selvin, John McEvoy
Journal: Journal of the American College of Cardiology (2017)
OUTCOMES OF FRACTIONAL FLOW RESERVE BASED DEFERRAL IN SAPHENOUS VEIN GRAFT LESIONS
Authors: Ahmed A. Almomani, Naga Venkata Pothineni, Mohan Mallik Edupuganti, Jason Payne, Shiv Kumar Agarwal, Barry Uretsky, Abdul Hakeem
Journal: Journal of the American College of Cardiology (2017)
Health consequences of the US Deferred Action for Childhood Arrivals (DACA) immigration programme: a quasi-experimental study
Authors: Atheendar S Venkataramani, Sachin J Shah, Rourke O'Brien, Ichiro Kawachi, Alexander C Tsai
Journal: The Lancet Public Health (2017)

The effects of changes in immigration policy on health outcomes among undocumented immigrants are not well known. We aimed to examine the physical and mental health effects of the Deferred Action for Childhood Arrivals (DACA) programme, a 2012 US immigration policy that provided renewable work permits and freedom from deportation for a large number of undocumented immigrants.
A NOVEL NECROPTOSIS INHIBITORS (NECROSULFONAMIDE AND NECROSTATIN-1S) DEMONSTRATE THERAPEUTIC POTENTIAL FOR MYOCARDIAL ISCHEMIA-REPERFUSION INJURY
Authors: Yuri Dmitriev, Sarkis Minasian, Valentina Bayrasheva, Elena Demchenko, Michael Galagudza
Journal: Journal of the American College of Cardiology (2017)
CORRELATION OF NONINVASIVE ASSESSMENT OF LUNG FLUID PERCENTAGE WITH INVASIVELY MEASURED HEMODYNAMICS
Authors: Nir Uriel, Gabriel Sayer, Gene Kim, Sirtaz Adatya, Nitasha Sarswat, Jayant Raikhelkar, Teruhiko Imamura, Daniel Rodergs, Ronnie Abbo, Daniel Burkhoff
Journal: Journal of the American College of Cardiology (2017)